About Us | Vantage Biomedical Partners

Leadership

Meet the Founders

Founded by Arvind Ravinutala, MD, and Aswini Ravinutala, BME — a physician and a biomedical engineer who review every full Vantage report. The Quick Screen is automated. Specialist consultation is available when an engagement needs it.

Arvind Ravinutala, MD

Co-Founder & Managing Partner

MD, Keck School of Medicine of USC | Board-certified internist | P&T Committee Chair and Associate Program Director, Adventist Health White Memorial | CMO, Fruit Street

Arvind Ravinutala, MD — practicing, board-certified internist with 14+ years of clinical, operational, academic and entrepreneurial leadership. Arvind leads the clinical and regulatory review on Vantage full reports.

At Adventist Health White Memorial, Arvind chairs the Pharmacy & Therapeutics (P&T) Committee, which reviews drugs and devices for adoption, serves as Associate Program Director for the Internal Medicine Residency, and previously served as Medical Director, Inpatient Medicine. Arvind has worked in clinical informatics at Adventist Health since 2021, is Chief Medical Officer of Fruit Street — providing clinical leadership for a CDC-recognized Diabetes Prevention Program — and serves on the Scientific Advisory Board of Spiro Medical, which is developing a pulmonary neuromodulation system for severe asthma.

Connect

Aswini Ravinutala, BME

Co-Founder & Partner

B.S. Biomedical Engineering, UC Irvine | M.Eng. Quality & Reliability Engineering, Arizona State University

Aswini Ravinutala, BME — biomedical engineer with 10+ years in medical devices: manufacturing, quality and reliability engineering at St. Jude Medical and Masimo, and operations engineering and management at Axonics through its 2024 acquisition by Boston Scientific. Aswini is currently R&D Manager at Spiro Medical.

At Vantage, Aswini leads the engineering review on full reports: design and verification strategy, manufacturing and supply-chain readiness, quality-system and regulatory-compliance maturity, and technical feasibility.

Connect

Disclosure: Spiro Medical. Arvind Ravinutala, MD, serves on Spiro Medical’s Scientific Advisory Board; Aswini Ravinutala, BME, is R&D Manager at Spiro Medical; and Spiro’s CEO, Rinda Sama, is a Vantage senior advisor. Vantage does not assess Spiro Medical or its direct competitors without disclosing these relationships.

How we think about diligence

Three lenses, applied to every full report

Vantage is new. The questions are not — they are the ones hospital committees and device engineers already ask.

The physician lens

A hospital committee weighing a new drug or device asks three things: Is it safer? Is it covered? Will staff actually use it? Full reports read every company against the same three.

The operator lens

Promising medtech can stall in regulatory review, supply-chain scaling or post-launch reimbursement. Full reports look at all three, not just the one the deck leads with.

The retrospective test

Before you trust a framework, see it applied to public cases. Our case-study library looks back at Theranos, Exactech, Pear Therapeutics and Owlet.

See the Quick Screen · $5,000 See a sample report

Assessment Coverage

Integrated MD + BME Evaluation

Every full report combines a physician’s clinical and regulatory review with a biomedical engineer’s technical review.

Clinical Assessment

Physician Leadership

Adoption & Workflow

Will physicians actually use it in practice?

Regulatory & Reimbursement

Is there a viable path to approval and coverage?

Clinical Evidence

Does the data support the clinical claims?

Competitive Positioning

How does it stack up against alternatives?

Technical Assessment

Engineering Leadership

Manufacturing & Scale

Can it be built reliably at production volume?

Quality & Compliance

Are quality systems mature enough for regulatory scrutiny?

IP & Technical Risk

Is the technology defensible and differentiated?

Supply Chain & Operations

Are there hidden sourcing or dependency risks?

Integrated

Vantage Index

Full reports summarize the eight domains in a composite index; the Quick Screen has none

Life Science Verticals

Four verticals

The same eight-domain method, applied to the regulatory and reimbursement realities of each vertical.

Medical Devices

510(k), De Novo and PMA pathways, predicates, manufacturing and quality readiness, reimbursement

Diagnostics

IVDs, LDTs and companion diagnostics, CLIA, clinical validation, coverage

Therapeutics

IND through NDA and BLA pathways, the clinical trial record, manufacturing readiness

Digital Health

SaMD classification, clinical decision support, cybersecurity, real-world evidence

Senior Advisor

Specialist Leadership

Advisor

Rinda Sama

Senior Advisor, Medical Device Operations & Commercialization

Rinda Sama was chief operating officer of Axonics for more than ten years and, before that, director of operations and quality at Vessix Vascular; both companies were later acquired by Boston Scientific. Rinda is a co-founder and the CEO of Spiro Medical and serves on the board of UroMems. M.S. Biomedical Engineering, University of Southern California; MBA, UC Irvine.

Rinda advises Vantage on medical device operations and commercialization. See the Spiro Medical disclosure above.

Our Story

Why We Started Vantage

Promising life science companies can stumble on regulatory, clinical, technical and reimbursement questions that were visible in the public record long before they became problems.

Reading that record well takes both clinical and engineering judgment, and it takes time most investors, founders and programs do not have.

Vantage was built to close that gap. By combining a physician’s understanding of clinical reality with a biomedical engineer’s rigor on technical execution, we assemble cited diligence on a company from the public record and the materials provided. We do not predict which companies will succeed; the earliest-stage outcomes turn on factors no dataset can foresee. What Vantage does is make the knowable risks legible — regulatory, clinical, technical and commercial — so investors and founders decide on the evidence rather than on the pitch.

Our Competitive Advantage

The Vantage Difference

Every full Vantage report is reviewed by a physician and a biomedical engineer, bringing clinical, regulatory, engineering and commercial questions into a single report with its sources attached.

24h

Quick Screen delivery after a complete intake

48h

Full report delivery after a complete intake

4

Verticals: devices, diagnostics, therapeutics and digital health

Our Methodology

How the analysis works

The Vantage platform assembles records from FDA, SEC, ClinicalTrials.gov, USPTO, CMS and other public sources — 3,900+ companies across 34 sources — into a structured eight-domain read, and compares a company with its closest peers. Reports are produced with the help of an outside AI provider, and every full report is reviewed by a physician and a biomedical engineer.

See our full methodology →

The Vantage Team